Ironwood Pharmaceuticals Appoints Edward Owens to Board of Directors

  Ironwood Pharmaceuticals Appoints Edward Owens to Board of Directors

Business Wire

CAMBRIDGE, Mass. -- March 4, 2013

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment
of Edward Owens to its board of directors. Mr. Owens is a recently retired
partner, portfolio manager and global industry analyst with Wellington
Management Company, LLP.

Edward Owens, Ironwood Board of Directors (Photo: Business Wire)

Edward Owens, Ironwood Board of Directors (Photo: Business Wire)

“Ed has gained a unique perspective on how to optimally allocate capital,
create value for shareholders and build and run successful businesses based on
nearly four decades of outstanding performance investing in healthcare
companies,” said Peter Hecht, chief executive officer of Ironwood. “He has
deeply probed the strategy, growth, successes and challenges of nearly every
company in the healthcare space during his investing career, and we are
thrilled to have the opportunity to tap into his insights, business savvy and
ownership focus.”

“I’ve closely followed Ironwood for eight years and have been a shareholder
since their IPO in 2010. During that time, I have had the opportunity to gain
a deep appreciation for Ironwood’s business acumen and long-term vision,” said
Mr. Owens. “I have been very impressed with the competence, entrepreneurial
spirit and high ethical standards of the management team. After decades of
observing companies from the outside, I am excited to be part of what I hope
and expect will be one of the next great growth companies in biotech. The
execution of a successful launch of LINZESS™ (linaclotide) should provide our
team with the resources to build an exceptional business, focused on improving
human health and advancing patient care.”

Mr. Owens started at Wellington in 1974 and served as portfolio manager for
the Vanguard Health Care Fund from its inception in May 1984 until his
retirement in December 2012. During his tenure, the Vanguard Health Care Fund
was the best performing mutual fund among all mutual funds. Consistently
outperforming the Lipper Global Health/Biotech Funds Average and the S&P 500
Index, it grew to be by far the largest mutual fund in the global
health/biotech category. Mr. Owens has a B.S. in Physics from the University
of Virginia and an M.B.A. from Harvard Business School. He has been recognized
numerous times for his investment performance and has been chosen twice as a
finalist for Morningstar's Fund Manager of the Year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical
company dedicated to the art and science of great drugmaking. Ironwood is
located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130304005523/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50582972&lang=en

Contact:

Ironwood Pharmaceuticals, Inc.
Media Relations
Lisa Buffington, 617.374.5103
Vice President, Corporate Communications
lbuffington@ironwoodpharma.com
or
Investor Relations
Meredith Kaya, 617.374.5082
Associate Director, Investor Relations
mkaya@ironwoodpharma.com
 
Press spacebar to pause and continue. Press esc to stop.